• 患者服务: 与癌共舞小助手
  • 微信号: yagw_help22

QQ登录

只需一步,快速开始

开启左侧

还没做过化疗,EGFR是野生型的病友一定要去做ALK的检测

  [复制链接]
187121 161 godblessmymum 发表于 2012-6-16 23:11:32 |
健康活着  小学五年级 发表于 2012-9-18 18:53:34 | 显示全部楼层 来自: 广东广州
落花无意  小学六年级 发表于 2012-9-22 15:56:39 | 显示全部楼层 来自: 上海
请问,肺鳞癌,只做过一次化疗,骨髓抑制严重,后吃特罗凯4个月基本无效,可以参加实验组吗?
godblessmymum  大学二年级 发表于 2012-9-24 20:13:39 | 显示全部楼层 来自: 上海虹口区
不可以了,要没做过任何治疗的,包括化疗和靶向药
老马  博士一年级 发表于 2012-10-14 22:18:42 | 显示全部楼层 来自: 浙江温州
Concomitant EGFR mutation and EML4-ALK gene fusion in non-small cell lung cancer.  Print this page    ~+ L: [1 R, R8 ~( c3 ]- g2 }7 b

4 k# O$ u, F; W' v/ s2 u& C' ^% r! n" u( Q4 e9 K6 h
Sub-category:3 v, p) `/ n3 E2 s, m
Molecular Targets " v4 p+ Q' Q( J

' }$ \; M; m, _. ^- c
1 O! S+ V  [# jCategory:9 p5 ]+ M7 t* Q8 c4 ?% M
Tumor Biology
* H2 G' I# t" c1 Q2 }$ J
5 b; \1 Q# q) ]" Z0 b2 d& p$ L
Meeting:! ^4 C+ R) k/ e& y! ~
2011 ASCO Annual Meeting 5 G) O& R7 Y2 t' }

; h. F0 O  v; z9 C" m$ C) h9 y$ k' [- }7 L6 V
Session Type and Session Title:1 M) n2 d$ j2 W7 V1 q  h  G( f. M4 S, M
Poster Discussion Session, Tumor Biology " v" c! G+ _& q4 a# [
& N* g1 K5 _+ R2 |/ J. B
6 ~$ ~6 z  d0 y4 _/ y# Z$ q
Abstract No:( D6 p7 J6 [* p4 G% j
10517 : X; A/ {/ S% R" D: \$ v

2 l# I% l  b6 M9 x" ?, A5 `1 v. c; s5 n, W4 O
Citation:
& a& i( Q; [' M+ nJ Clin Oncol 29: 2011 (suppl; abstr 10517) " l: F+ q: G+ H2 \8 ~/ f
4 v7 ?8 J. [6 I% \$ d' d& H7 t1 l
* z2 {) I8 q4 z* U- Q& b. a
Author(s):
7 l; f6 G, r; D- vJ. Yang, X. Zhang, J. Su, H. Chen, H. Tian, Y. Huang, C. Xu, Y. L. Wu; Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China; Guangdong Lung Cancer Institute, Medical Research Center of Guangdong General Hospital, Guangzhou, China; Guangdong Lung Cancer Institute, Guangzhou, China; Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China 5 _! |4 o+ e: ~; G) l" p
" `* g3 x# |: c8 S

9 Z9 t. ~/ t* a" w8 z! D7 C& E' H  y; m* I" w# h" v& M
Abstracts that were granted an exception in accordance with ASCO's Conflict of Interest Policy are designated with a caret symbol (^) here and in the printed Proceedings.3 G! h. a$ J# j% I
4 S5 t" |5 d- e9 i2 d" z
Abstract Disclosures
" |4 p! ~5 x- _; F( r) r6 Y4 i- R) F/ J$ ^. ]
Abstract:
# V. x) i* q( U. s0 m2 ]5 f3 _) G( |3 E

6 k" ~; t+ F+ lBackground: The fusion of the anaplastic lymphoma kinase (ALK) with the echinoderm microtubule-associated protein-like 4 (EML4) and epidermal growth factor receptor (EGFR) mutations are considered mutually exclusive. Advanced non-small cell lung cancer (NSCLC) patients with EML4-ALK did not benefit from EGFR tyrosine kinase inhibitors (TKIs). Methods: Multiplex reverse transcriptase-polymerase chain reaction (RT-PCR) followed by sequencing was performed for EML4-ALK fusion status detection. EGFR and KRAS mutations were determined by direct DNA sequencing. Positive results of EML4-ALK fusion were also confirmed by RACE-coupled PCR sequencing. Results: From April 2010 to January 2011, 412 patients (398 with NSCLC; 14 with SCLC) were tested for mutation status of EGFR, KRAS and EML4-ALK respectively. Frequency of EML4-ALK fusion was 10.6% (42/398) in NSCLC patients. No patients with SCLC were found to have positive EML4-ALK fusion. Frequency of concomitant EGFR and EML4-ALK gene mutations was 1.0% (4/398) in NSCLC patients, and their variants of EML4-ALK gene mutations were Variant 1 (3 patients) and Variant 6 (1 patient); being never smokers, all of them were diagnosed with advanced (3 with stage †W and 1 with stage IIIB) adenocarcinoma harbouring wild type KRAS. Two female stage †W patients with double gene mutations (1 with L858R and Variant 1; 1 with exon19 deletion and Variant 6) received first-line gefitinib which is one kind of EGFR TKIs and achieved partial response. Conclusions: Though being rare events, NSCLC patients harbouring concomitant EGFR mutation and EML4-ALK gene fusion are sensitive to first-line EGFR TKIs. Whether they could also benefit from ALK inhibition after failure to EGFR TKIs warranted further investigation.
4 D1 l* }+ F$ I, P6 x
- [: j! \. g& H" W! A( y * r6 ~3 b9 d9 ?, W7 \
个人公众号:treeofhope
累计签到:8 天
连续签到:1 天
[LV.3]与爱熟人
一只白杨  大学一年级 发表于 2012-11-15 17:48:59 | 显示全部楼层 来自: 广东广州
由吴一龙教授牵头的A80810029临床试验上周启动,初诊未治疗的晚期肺腺癌患者检测到ALK阳性,可参加一线crizotinib 对比力比泰+卡铂的临床研究,药物全部免费,即使分配到力比泰组,疾病进展之后可免费获得crizotinib.
boeun  小学四年级 发表于 2012-11-18 16:37:21 | 显示全部楼层 来自: 福建泉州
没有手术,只化疗过,现吃靶向药,未突变,alk未测,有机会入组吗?
godblessmymum  大学二年级 发表于 2012-11-18 23:23:21 | 显示全部楼层 来自: 上海杨浦区
boeun 发表于 2012-11-18 16:37 ( c+ [) u4 B6 y* f; h5 }: t! M
没有手术,只化疗过,现吃靶向药,未突变,alk未测,有机会入组吗?

# m& e5 |7 F8 n; [. H化疗过的没机会了
helpU  高中三年级 发表于 2012-12-3 21:04:24 | 显示全部楼层 来自: 北京
平安! 发表于 2012-7-20 11:20
7 i! S+ @" S0 _3 S" k9 d. A7 o- Z易瑞沙、特罗凯有效的病人基本上可以断定ALK(-)。极其罕见EGFR、ALK同时突变的。  T9 o* p/ D9 n( c. |4 E$ M
ALK一个指标医院要900多 ...

' I& Z8 W) y- I1 E平安,真的没有希望吗?我弟弟虽然特罗凯有效,但是EGFR是野生型,不是突变啊。有没有必要去检测ALK呢?
0 _9 w% o2 |3 H& K  c- t- Z% e: F0 K
现在病情进展,快没招儿了。
294170420  初中二年级 发表于 2012-12-4 22:04:38 | 显示全部楼层 来自: 浙江丽水
好像想加入挺困难的
wdc2482  小学六年级 发表于 2012-12-19 18:47:22 | 显示全部楼层 来自: 青海西宁
小地方没条件做啊

举报 使用道具

回复 支持 0 反对 1

发表回复

您需要登录后才可以回帖 登录 | 立即注册

本版积分规则

  • 回复
  • 转播
  • 评分
  • 分享
帮助中心
网友中心
购买须知
支付方式
服务支持
资源下载
售后服务
定制流程
关于我们
关于我们
友情链接
联系我们
关注我们
官方微博
官方空间
微信公号
快速回复 返回顶部 返回列表